Korro Bio, Inc.
KRRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703647
In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 8 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Korro Bio, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 41 | 42 | +1 |
| Shares | 4.83M | 10.6M | +5.77M (+119.5%) |
| Value | $1.67M | $2.58M | +$913.0K (+54.7%) |
New holders (8)
Institutions that held Korro Bio, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 1,200,000 | $444.0K | 0.00% |
| Goldman Sachs Group Inc | 212,082 | $78.5K | 0.00% |
| XTX Topco Ltd | 30,030 | $11.0K | 0.00% |
| HRT Financial LP | 14,700 | $5.00K | 0.00% |
| Two Sigma Advisers, LP | 10,200 | $3.77K | 0.00% |
| Orion Capital Management LLC | 1,000 | $370 | 0.00% |
| Qube Research & Technologies Ltd | 2 | $1 | 0.00% |
| Eventide Asset Management, LLC | 3,597,122 | – | – |
Sold out (7)
Institutions that held Korro Bio, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| GTS Securities LLC | 223,278 | $77.3K |
| Millennium Management LLC | 83,305 | $28.8K |
| Northeast Financial Consultants Inc | 42,857 | $14.8K |
| Raymond James & Associates | 26,000 | $9.00K |
| StoneX Group Inc. | 14,504 | $5.02K |
| Tower Research Capital LLC (TRC) | 13,226 | $4.58K |
| Rhumbline Advisers | 1,058 | $366 |